The Inflammatory Response to Cardiopulmonary Bypass: Part 2-Anti-Inflammatory Therapeutic Strategies

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 23, Issue 3, 2009, Pages 384-393

  Warren, Oliver J ^a   Watret, Amy L ^a   de Wit, Katie L ^a   Alexiou, Christos ^b   Vincent, Charles ^a   Darzi, Ara W ^a   Athanasiou, Thanos ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

cardiac; cardiopulmonary bypass; cells; inflammation; surgery

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; AMINOCAPROIC ACID; ANESTHETIC GAS; ANTICOAGULANT AGENT; ANTIOXIDANT; APROTININ; ASCORBIC ACID; CARBON MONOXIDE; CARDIOVASCULAR AGENT; COMPLEMENT INHIBITOR; CORTICOSTEROID; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPEXAMINE; GLYCOSAMINOGLYCAN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MANNITOL; MILRINONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; SCR1SLE; SERINE PROTEINASE INHIBITOR; STEROID; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANESTHESIA; ANTIOXIDANT ACTIVITY; BLOOD CONSERVATION; BLOOD FILTER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CATHETERIZATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS GRAFT; DISEASE PREDISPOSITION; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INDEX; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEMODILUTION; HEMORRHAGIC SHOCK; HEPARINIZATION; HUMAN; HYPOTHERMIA; INTENSIVE CARE; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; NONHUMAN; OFF PUMP CORONARY SURGERY; ORGAN INJURY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; ULTRAFILTRATION;

ANTI-INFLAMMATORY AGENTS; CARDIOPULMONARY BYPASS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 67349158086     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2008.09.007     Document Type: Review

References (149)

1. Replogle R.L., Gazzaniga A.B., and Gross R.E. Use of corticosteroids during cardiopulmonary bypass: Possible lysosome stabilization. Circulation 33 (1966) I86-I92
2. Sambhi M.P., Weil M.H., and Udhoji V.N. Acute pharmacodynamic effects of glucocorticoids; Cardiac output and related hemodynamic changes in normal subjects and patients in shock. Circulation 31 (1965) 523-530
3. Christman J.W., Holden E.P., and Blackwell T.S. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23 (1995) 955-963
4. von Spiegel T., Giannaris S., Wietasch G.J., et al. Effects of dexamethasone on intravascular and extravascular fluid balance in patients undergoing coronary bypass surgery with cardiopulmonary bypass. Anesthesiology 96 (2002) 827-834
5. Cronstein B.N., Kimmel S.C., Levin R.I., et al. A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 89 (1992) 9991-9995
6. Tennenberg S.D., Bailey W.W., Cotta L.A., et al. The effects of methylprednisolone on complement-mediated neutrophil activation during cardiopulmonary bypass. Surgery 100 (1986) 134-142
7. Teoh K.H., Bradley C.A., Gauldie J., et al. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 92 (1995) II347-II353
8. Kawamura T., Inada K., Nara N., et al. Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med 27 (1999) 545-548
9. Jansen N.J., van Oeveren W., van den Broek L., et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 102 (1991) 515-525
10. El Azab S.R., Rosseel P.M., de Lange J.J., et al. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br J Anaesth 88 (2002) 496-501
11. Toft P., Christiansen K., Tonnesen E., et al. Effect of methylprednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery. Scand Cardiovasc J 31 (1997) 283-288
12. Kawamura T., Inada K., Okada H., et al. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 42 (1995) 399-403
13. Fillinger M.P., Rassias A.J., Guyre P.M., et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth 16 (2002) 163-169
14. Halonen J., Halonen P., Jarvinen O., et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA 297 (2007) 1562-1567
15. Augoustides J.G. Use of corticosteroids to prevent atrial fibrillation after cardiac surgery. JAMA 298 (2007) 283
16. Chaney M.A. Corticosteroids and cardiopulmonary bypass: A review of clinical investigations. Chest 121 (2002) 921-931
17. Chaney M.A., Durazo-Arvizu R.A., Nikolov M.P., et al. Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. J Thorac Cardiovasc Surg 121 (2001) 561-569
18. Chaney M.A., Nikolov M.P., Blakeman B., et al. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 87 (1998) 27-33
19. Chaney M.A., Nikolov M.P., Blakeman B.P., et al. Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Ann Thorac Surg 67 (1999) 1006-1011
20. Morariu A.M., Loef B.G., Aarts L.P., et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: A study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 128 (2005) 2677-2687
21. Robertson-Malt S., Afrane B., and El Barbary M. Prophylactic steroids for pediatric open heart surgery. Cochrane Database Syst Rev (2007) CD005550
22. Eagle K.A., Guyton R.A., Davidoff R., et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110 (2004) e340-e437
23. Castiglioni G.C., Lojacono L., and Tamborini G. [Effects of trypsin and kallikrein inhibition in acute pancreatitis]. Arch Ital Chir 91 (1965) 365-376
24. Bidstrup B.P., Royston D., Sapsford R.N., et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97 (1989) 364-372
25. Bidstrup B.P., Royston D., Taylor K.M., et al. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery. Lancet 1 (1988) 366-367
26. Royston D., Bidstrup B.P., Taylor K.M., et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2 (1987) 1289-1291
27. Day J.R., and Taylor K.M. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 3 (2005) 129-140
28. Poullis M., Manning R., Laffan M., et al. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 120 (2000) 370-378
29. Greilich P.E., Brouse C.F., Whitten C.W., et al. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: A randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 126 (2003) 1498-1503
30. Hill G.E., Pohorecki R., Alonso A., et al. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 83 (1996) 696-700
31. Ege T., Arar C., Canbaz S., et al. The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 52 (2004) 10-15
32. Wendel H.P., Heller W., Michel J., et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 109 (1995) 1164-1172
33. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
34. Mangano D.T., Rieves R.D., and Weiss K.D. Judging the safety of aprotinin. N Engl J Med 355 (2006) 2261-2262
35. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
36. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
37. Sedrakyan A., Atkins D., and Treasure T. The risk of aprotinin: A conflict of evidence. Lancet 367 (2006) 1376-1377
38. Fergusson D.A., Hebert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
39. Ray W.A., and Stein C.M. The aprotinin story-Is BART the final chapter?. N Engl J Med 358 (2008) 2398-2400
40. Collard C.D., and Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 94 (2001) 1133-1138
41. Pintar T., and Collard C.D. The systemic inflammatory response to cardiopulmonary bypass. Anesthesiol Clin North Am 21 (2003) 453-464
42. Sun S.C., Appleyard R., Masetti P., et al. Improved recovery of heart transplants by combined use of oxygen-derived free radical scavengers and energy enhancement. J Thorac Cardiovasc Surg 104 (1992) 830-837
43. Julia P.L., Buckberg G.D., Acar C., et al. Studies of controlled reperfusion after ischemia. XXI. Reperfusate composition: Superiority of blood cardioplegia over crystalloid cardioplegia in limiting reperfusion damage-Importance of endogenous oxygen free radical scavengers in red blood cells. J Thorac Cardiovasc Surg 101 (1991) 303-313
44. Yau T.M., Weisel R.D., Mickle D.A., et al. Vitamin E for coronary bypass operations. A prospective, double-blind, randomized trial. J Thorac Cardiovasc Surg 108 (1994) 302-310
45. Sisto T., Paajanen H., Metsa-Ketela T., et al. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 59 (1995) 1519-1523
46. Shernan S.K., Fitch J.C., Nussmeier N.A., et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77 (2004) 942-949
47. Smith P.K., Carrier M., Chen J.C., et al. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg 82 (2006) 781-788
48. Carrier M., Menasche P., Levy J.H., et al. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg 131 (2006) 352-356
49. Verrier E.D., Shernan S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 291 (2004) 2319-2327
50. Mollhoff T., Loick H.M., Van Aken H., et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 90 (1999) 72-80
51. Hayashida N., Tomoeda H., Oda T., et al. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 68 (1999) 1661-1667
52. Massoudy P., Zahler S., Barankay A., et al. Sodium nitroprusside during coronary artery bypass grafting: Evidence for an antiinflammatory action. Ann Thorac Surg 67 (1999) 1059-1064
53. Paparella D., Yau T.M., and Young E. Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21 (2002) 232-244
54. Murphy G.S., Szokol J.W., Marymont J.H., et al. The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery. Anesth Analg 104 (2007) 1334-1342
55. Stammberger U., Hamacher J., Pache J.C., et al. sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection. Eur J Cardiothorac Surg 22 (2002) 368-372
56. Gott V.L., Whiffen J.D., and Dutton R.C. Heparin bonding on colloidal graphite surfaces. Science 142 (1963) 1297-1298
57. Gott V.L., and Daggett R.L. Serendipity and the development of heparin and carbon surfaces. Ann Thorac Surg 68 (1999) S19-S22
58. Mollnes T.E., Videm V., Gotze O., et al. Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann Thorac Surg 52 (1991) 92-97
59. Ovrum E., Fosse E., Mollnes T.E., et al. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg 10 (1996) 54-60
60. Steinberg B.M., Grossi E.A., Schwartz D.S., et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 60 (1995) 525-529
61. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
62. Mahoney C.B., and Lemole G.M. Transfusion after coronary artery bypass surgery: The impact of heparin-bonded circuits. Eur J Cardiothorac Surg 16 (1999) 206-210
63. Ranucci M., Cirri S., Conti D., et al. Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. Ann Thorac Surg 61 (1996) 76-81
64. Mongero L.B., Beck J.R., Manspeizer H.E., et al. Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to non-heparin-bonded circuits. Perfusion 16 (2001) 107-111
65. Belboul A., Lofgren C., Storm C., et al. Heparin-coated circuits reduce occult myocardial damage during CPB: A randomized, single blind clinical trial. Eur J Cardiothorac Surg 17 (2000) 580-586
66. Ranucci M., Mazzucco A., Pessotto R., et al. Heparin-coated circuits for high-risk patients: A multicenter, prospective, randomized trial. Ann Thorac Surg 67 (1999) 994-1000
67. Fosse E., Thelin S., Svennevig J.L., et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: A European multicentre study. Eur J Cardiothorac Surg 11 (1997) 320-327
68. Boonstra P.W., Gu Y.J., Akkerman C., et al. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg 107 (1994) 289-292
69. Mangoush O., Purkayastha S., Haj-Yahia S., et al. Heparin-bonded circuits versus nonheparin-bonded circuits: An evaluation of their effect on clinical outcomes. Eur J Cardiothorac Surg 31 (2007) 1058-1069
70. Baker R.A., and Willcox T.W. Australian and New Zealand perfusion survey: Equipment and monitoring. J Extra Corpor Technol 38 (2006) 220-229
71. Stammers A.H., and Mejak B.L. An update on perfusion safety: Does the type of perfusion practice affect the rate of incidents related to cardiopulmonary bypass?. Perfusion 16 (2001) 189-198
72. Karkouti K., Beattie W.S., Wijeysundera D.N., et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 129 (2005) 391-400
73. Mathew J.P., Mackensen G.B., Phillips-Bute B., et al. Effects of extreme hemodilution during cardiac surgery on cognitive function in the elderly. Anesthesiology 107 (2007) 577-584
74. Habib R.H., Zacharias A., Schwann T.A., et al. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: Should current practice be changed?. J Thorac Cardiovasc Surg 125 (2003) 1438-1450
75. Kiziltepe U., Uysalel A., Corapcioglu T., et al. Effects of combined conventional and modified ultrafiltration in adult patients. Ann Thorac Surg 71 (2001) 684-693
76. Journois D., Israel-Biet D., Pouard P., et al. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 85 (1996) 965-976
77. Journois D., Pouard P., Greeley W.J., et al. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components. Anesthesiology 81 (1994) 1181-1189
78. Saatvedt K., Lindberg H., Geiran O.R., et al. Ultrafiltration after cardiopulmonary bypass in children: Effects on hemodynamics, cytokines and complement. Cardiovasc Res 31 (1996) 596-602
79. Boga M., Islamoglu, Badak I., et al. The effects of modified hemofiltration on inflammatory mediators and cardiac performance in coronary artery bypass grafting. Perfusion 15 (2000) 143-150
80. Blanchard N., Toque Y., Trojette F., et al. Hemodynamic and echocardiographic effects of hemofiltration performed during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 14 (2000) 393-398
81. Aggarwal N.K., Das S.N., Sharma G., et al. Efficacy of combined modified and conventional ultrafiltration during cardiac surgery in children. Ann Card Anaesth 10 (2007) 27-33
82. Groom R.C., Froebe S., Martin J., et al. Update on pediatric perfusion practice in North America: 2005 survey. J Extra Corpor Technol 37 (2005) 343-350
83. Belway D., Rubens F.D., Wozny D., et al. Are we doing everything we can to conserve blood during bypass?. A national survey. Perfusion 20 (2005) 237-241
84. Grunenfelder J., Zund G., Schoeberlein A., et al. Modified ultrafiltration lowers adhesion molecule and cytokine levels after cardiopulmonary bypass without clinical relevance in adults. Eur J Cardiothorac Surg 17 (2000) 77-83
85. Kamada M., Niibori K., Akimoto H., et al. Efficacy of modified ultrafiltration in coronary artery bypass grafting. Kyobu Geka 54 (2001) 463-467
86. Otaki M., Enmoto T., and Oku H. Coronary bypass grafting for patients dependent on dialysis: modified ultrafiltration for perioperative management. ASAIO J 49 (2003) 650-654
87. Kuntz R.A., Holt D.W., Turner S., et al. Effects of conventional ultrafiltration on renal performance during adult cardiopulmonary bypass procedures. J Extra Corpor Technol 38 (2006) 144-153
88. Luciani G.B., Menon T., Vecchi B., et al. Modified ultrafiltration reduces morbidity after adult cardiac operations: A prospective, randomized clinical trial. Circulation 104 (2001) I253-I259
89. Onoe M., Magara T., Yamamoto Y., et al. Modified ultrafiltration removes serum interleukin-8 in adult cardiac surgery. Perfusion 16 (2001) 37-42
90. Boodhwani M., Williams K., Babaev A., et al. Ultrafiltration reduces blood transfusions following cardiac surgery: A meta-analysis. Eur J Cardiothorac Surg 30 (2006) 892-897
91. Williams G.D., Ramamoorthy C., Chu L., et al. Modified and conventional ultrafiltration during pediatric cardiac surgery: Clinical outcomes compared. J Thorac Cardiovasc Surg 132 (2006) 1291-1298
92. Chew M.S. Does modified ultrafiltration reduce the systemic inflammatory response to cardiac surgery with cardiopulmonary bypass?. Perfusion 19 suppl 1 (2004) S57-S60
93. Gaynor J.W. The effect of modified ultrafiltration on the postoperative course in patients with congenital heart disease. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 6 (2003) 128-139
94. Schueler S., De Valeria P.A., Hatanaka M., et al. Successful twenty-four-hour lung preservation with donor core cooling and leukocyte depletion in an orthotopic double lung transplantation model. J Thorac Cardiovasc Surg 104 (1992) 73-82
95. Bando K., Pillai R., Cameron D.E., et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 99 (1990) 873-877
96. Bando K., Schueler S., Cameron D.E., et al. Twelve-hour cardiopulmonary preservation using donor core cooling, leukocyte depletion, and liposomal superoxide dismutase. J Heart Lung Transplant 10 (1991) 304-309
97. Palanzo D., Manley N., Montesano R., et al. Clinical Evaluation of the LeukoGuard (LG-6) arterial line filter for routine open-heart surgery. Perfusion 8 (1993) 489-496
98. Gu Y.J., de Vries A.J., Vos P., et al. Leukocyte depletion during cardiac operation: A new approach through the venous bypass circuit. Ann Thorac Surg 67 (1999) 604-609
99. Sawa Y., Matsuda H., Shimazaki Y., et al. Evaluation of leukocyte-depleted terminal blood cardioplegic solution in patients undergoing elective and emergency coronary artery bypass grafting. J Thorac Cardiovasc Surg 108 (1994) 1125-1131
100. Salamonsen R.F., Anderson J., Anderson M., et al. Total leukocyte control for elective coronary bypass surgery does not improve short-term outcome. Ann Thorac Surg 79 (2005) 2032-2038
101. Scholz M., Simon A., Matheis G., et al. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 51 (2002) 363-368
102. Alexiou C., Sheppard S., Smith D., et al. Effect of blood temperature on the efficacy of systemic leukodepletion during cardiopulmonary bypass: A prospective randomized clinical study. ASAIO J 51 (2005) 802-807
103. Gott J.P. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion 16 suppl (2001) 5-9
104. Warren O., Alexiou C., Massey R., et al. The effects of various leukocyte filtration strategies in cardiac surgery. Eur J Cardiothorac Surg 31 (2007) 665-676
105. Tang A.T., Alexiou C., Hsu J., et al. Leukodepletion reduces renal injury in coronary revascularization: A prospective randomized study. Ann Thorac Surg 74 (2002) 372-377
106. Matheis G., Scholz M., Gerber J., et al. Leukocyte filtration in the early reperfusion phase on cardiopulmonary bypass reduces myocardial injury. Perfusion 16 (2001) 43-49
107. Pearl J.M., Drinkwater D.C., Laks H., et al. Leukocyte-depleted reperfusion of transplanted human hearts: A randomized, double-blind clinical trial. J Heart Lung Transplant 11 (1992) 1082-1092
108. Lust R.M., Bode A.P., Yang L., et al. In-line leukocyte filtration during bypass. Clinical results from a randomized prospective trial. ASAIO J 42 (1996) M819-M822
109. Alexiou C., Tang A.A., Sheppard S.V., et al. The effect of leucodepletion on leucocyte activation, pulmonary inflammation and respiratory index in surgery for coronary revascularisation: A prospective randomised study. Eur J Cardiothorac Surg 26 (2004) 294-300
110. Warren O.J., Tunnicliffe C.R., Massey R.M., et al. Systemic leukofiltration does not attenuate pulmonary injury after cardiopulmonary bypass. ASAIO J 54 (2008) 78-88
111. Warren O., Darzi A., and Athanasiou T. What is the role of leukocyte depletion in cardiac surgery?. Heart Lung Circ 16 (2007) 398-399
112. Lim H.K., Anderson J., Leong J.Y., et al. What is the role of leukocyte depletion in cardiac surgery?. Heart Lung Circ 16 (2007) 243-253
113. Andersen K.S., Nygreen E.L., Grong K., et al. Comparison of the centrifugal and roller pump in elective coronary artery bypass surgery-A prospective, randomized study with special emphasis upon platelet activation. Scand Cardiovasc J 37 (2003) 356-362
114. Alamanni F., Parolari A., Zanobini M., et al. Centrifugal pump and reduction of neurological risk in adult cardiac surgery. J Extra Corpor Technol 33 (2001) 4-9
115. Klein M., Dauben H.P., Schulte H.D., et al. Centrifugal pumping during routine open heart surgery improves clinical outcome. Artif Organs 22 (1998) 326-336
116. Klein M., Mahoney C.B., Probst C., et al. Blood product use during routine open heart surgery: the impact of the centrifugal pump. Artif Organs 25 (2001) 300-305
117. Dickinson T.A., Prichard J., and Rieckens F. A comparison of the benefits of roller pump versus constrained vortex pump in adult open-heart operations utilizing outcomes research. J Extra Corpor Technol 26 (1994) 108-113
118. Menasche P., Peynet J., Haeffner-Cavaillon N., et al. Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass. Circulation 92 (1995) II334-II340
119. Menasche P., Peynet J., Lariviere J., et al. Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions?. Circulation 90 (1994) II275-II279
120. Birdi I., Caputo M., Underwood M., et al. The effects of cardiopulmonary bypass temperature on inflammatory response following cardiopulmonary bypass. Eur J Cardiothorac Surg 16 (1999) 540-545
121. McLean R.F., and Wong B.I. Normothermic versus hypothermic cardiopulmonary bypass: Central nervous system outcomes. J Cardiothorac Vasc Anesth 10 (1996) 45-52
122. Grigore A.M., Mathew J., Grocott H.P., et al. Prospective randomized trial of normothermic versus hypothermic cardiopulmonary bypass on cognitive function after coronary artery bypass graft surgery. Anesthesiology 95 (2001) 1110-1119
123. Investigators TWH. Randomised trial of normothermic versus hypothermic coronary bypass surgery. Lancet 343 (1994) 559-563
124. Shann K.G., Likosky D.S., Murkin J.M., et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 132 (2006) 283-290
125. Engoren M.C., Habib R.H., Zacharias A., et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74 (2002) 1180-1186
126. Ferraris V.A., and Ferraris S.P. Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Tex Heart Inst J 22 (1995) 216-230
127. Murphy P.J., Connery C., Hicks Jr. G.L., et al. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 104 (1992) 1092-1099
128. Silliman C.C., Boshkov L.K., Mehdizadehkashi Z., et al. Transfusion-related acute lung injury: Epidemiology and a prospective analysis of etiologic factors. Blood 101 (2003) 454-462
129. Ekert H., Brizard C., Eyers R., et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 17 (2006) 389-395
130. Warren O., Wallace S., Massey R., et al. Does systemic leukocyte filtration affect perioperative haemorrhage in cardiac surgery?. A systematic review and meta-analysis. ASAIO J 53 (2007) 514-521
131. Raja S.G., and Dreyfus G.D. Impact of off-pump coronary artery bypass surgery on postoperative bleeding: Current best available evidence. J Card Surg 21 (2006) 35-41
132. Ferraris V.A., Ferraris S.P., Saha S.P., et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 83 (2007) S27-S86
133. Goebel U., Siepe M., Mecklenburg A., et al. Carbon monoxide inhalation reduces pulmonary inflammatory response during cardiopulmonary bypass in pigs. Anesthesiology 108 (2008) 1025-1036
134. Lavitrano M., Smolenski R.T., Musumeci A., et al. Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs. FASEB J 18 (2004) 1093-1095
135. Siepe M., Goebel U., Mecklenburg A., et al. Pulsatile pulmonary perfusion during cardiopulmonary bypass reduces the pulmonary inflammatory response. Ann Thorac Surg 86 (2008) 115-122
136. Ng C.S., Arifi A.A., Wan S., et al. Ventilation during cardiopulmonary bypass: Impact on cytokine response and cardiopulmonary function. Ann Thorac Surg 85 (2008) 154-162
137. Angelini G.D., Taylor F.C., Reeves B.C., et al. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): A pooled analysis of two randomised controlled trials. Lancet 359 (2002) 1194-1199
138. Nathoe H.M., van Dijk D., Jansen E.W., et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348 (2003) 394-402
139. Straka Z., Widimsky P., Jirasek K., et al. Off-pump versus on-pump coronary surgery: Final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg 77 (2004) 789-793
140. Cheng D.C., Bainbridge D., Martin J.E., et al. Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass?. A meta-analysis of randomized trials. Anesthesiology 102 (2005) 188-203
141. Lee J.D., Lee S.J., Tsushima W.T., et al. Benefits of off-pump bypass on neurologic and clinical morbidity: A prospective randomized trial. Ann Thorac Surg 76 (2003) 18-25
142. Parolari A., Alamanni F., Cannata A., et al. Off-pump versus on-pump coronary artery bypass: Meta-analysis of currently available randomized trials. Ann Thorac Surg 76 (2003) 37-40
143. Raja S.G., and Berg G.A. Impact of off-pump coronary artery bypass surgery on systemic inflammation: Current best available evidence. J Card Surg 22 (2007) 445-455
144. Matata B.M., Sosnowski A.W., and Galinanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg 69 (2000) 785-791
145. Diegeler A., Doll N., Rauch T., et al. Humoral immune response during coronary artery bypass grafting: A comparison of limited approach, "off-pump" technique, and conventional cardiopulmonary bypass. Circulation 102 (2000) III95-II100
146. Wan I.Y., Arifi A.A., Wan S., et al. Beating heart revascularization with or without cardiopulmonary bypass: Evaluation of inflammatory response in a prospective randomized study. J Thorac Cardiovasc Surg 127 (2004) 1624-1631
147. Wehlin L., Vedin J., Vaage J., et al. Activation of complement and leukocyte receptors during on- and off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg 25 (2004) 35-42
148. Al-Ruzzeh S., Hoare G., Marczin N., et al. Off-pump coronary artery bypass surgery is associated with reduced neutrophil activation as measured by the expression of CD11b: A prospective randomized study. Heart Surg Forum 6 (2003) 89-93
149. Dorman B.H., Kratz J.M., Multani M.M., et al. A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth 18 (2004) 25-29